Podcasts about Cras

Aujourd'hui, Flora Ghebali, entrepreneure dans la transition écologique, Barbara Lefebvre, prof d'histoire-géo, et Didier Giraud, éleveur de bovins, débattent de l'actualité autour d'Olivier Truchot.

Dr. Deb Muth 00:02What if I told you that before a single drop of chemotherapy goes into a cancer patient’s body, we can take a blood sample, grow their actual living cancer cells in a lab, and test 70 different drugs against those cells, all outside the patient’s body, to find out which ones actually work. And what if I told you that the conventional oncology doesn’t routinely use this test? Well, today we’re going to talk about why that matters and we’re going to go through and I’m going to share a story that is very personal to me. It’s about a 38 year old man with a rare complex cancer diagnosis and the precision testing that is helping to keep that cancer from progressing. Stay with me. This is one that is going to change how you think about cancer treatment. Dr. Deb Muth 01:05You guys can put a little ad right in here before we start the next segment here. Hey everybody, welcome back to Let’s Talk Wellness Now. I’m Dr. Deb and today we’re going deep. I mean really deep. It’s some of the most cutting edge cancer testing I have ever seen in clinical practice. Now, normally I don’t talk about cancer. And I would not be sharing this story if it was anyone other than my own family. I do have permission to share and talk about this publicly. So I want to do this. I want to make sure that I share this message. And he is giving his blessing to share this story because we both believe that it can save lives. So his name is Cameron. He’s 38 years old. And he is my son-in-law. And two years ago, he came to me with a small lymph node underneath his arm and a bullseye rash. So of course, being the lime literate person that I am, my first inclination was to say, yeah, this makes sense. You have an enlarged lymph node because you have this bullseye rash. You got bit by the tick. Let’s keep an eye on it. If it doesn’t go away, let me know. So Fast forward a year and a half later, he comes to me and says, mom, what do you think about this? This thing is getting a little bit larger. And I said, yeah, it’s a little larger. Not sure. Let’s keep an eye on it. He wasn’t feeling anything. All his labs looked okay. And then one day he was out chopping wood and he started getting numbness in that arm and he felt it again. And it had exploded in size. And so after some evaluation with my daughter and him, we decided to do a ultrasound. And we thought what was going to come back was a fatty tumor. It felt like one looks like one responded to one. He’s 38 years old. He’s healthy. There’s nothing in our mind that’s ever thinking the result that we’re going to get back. Dr. Deb Muth 03:28Is a possible lymphoma. Needless to say, we were shocked by that ultrasound result. And we go fast forward, we have the biopsy. I requested a total excisional biopsy. I was told by the oncologist that that was old school. They don’t do that that way anymore. And I need to stay out of this. I need to let the experts take care of this because that’s what they do best. And this came from a breast surgeon here in Wisconsin. And so I stepped back for a moment. I let him do his biopsy and what came back was adenocarcinoma of an unknown origin. Had we excised the entire lymph node, we would have had more tissue to work with. I think we could have gotten a better diagnosis. So over the course of the next two and a half, three months, we have some more imaging done. We have some more testing done. They send a pathology out to Mayo Clinic. And what continues to come back is this incongruent test results. If anybody’s ever had this, it’s extremely frustrating. One test shows lymphoma. Now it shows breast cancer. Then the next week it shows estrogen receptor HER2 positive breast cancer. Two weeks later, another test comes back and it says, no, it’s not HER2, it’s triple negative breast cancer. And now it looks like it’s out of the lymph nodes. Now it looks like it’s in the lymph nodes. And we do a PET scan and they can’t find cancer anywhere except in this axilla area. But now we find a lymph node on the right side. So it must have spread.Let’s go ahead and do a biopsy on that. And so they biopsy the right side and the right side comes back with nothing other than tattoo ink. Now, all of this is kind of crazy. I am not a cancer specialist. I want to start by saying that I am not a cancer specialist. What I am sharing today is from a mother-in-law’s perspective, from a medical detective’s perspective, I do know how to do research. I do know how to find answers. And so what I’m going to share with you Dr. Deb Muth 05:54Is totally my opinion and totally my experience. And I’m not telling anybody to do anything different than what their doctors are telling them to do. But I am telling you to ask questions. So I go deep down the rabbit hole and find out that Tattoo Ink can appear like metastatic cancer on a PET scan. And we all know everybody gets tattoos today. They’re all over everyone. And yet we’re not thinking about how this tattoo ink can cause problems for us down the road, not to mention that there are heavy metals in them and it’s a toxin and it’s creating an inflammatory process in your body that your body’s constantly trying to get rid of. So the surgeon says to us, well, yes, that’s normal that that lymph nodes inflamed. It’s normal that there’s tattoo ink in it. The body’s doing what it’s supposed to do. It’s trying to get rid of a toxin. Okay. I will agree with that, but My son-in-law is covered with tattoos everywhere. And why didn’t we mention the tattoo ink that was found in the left axilla? We are only mentioning it in the right axilla. So there’s a lot of controversy, a lot of confusion. Many of you would never know any of this because A, you either don’t look at your lab results. And if you do, you don’t understand what you’re looking at. And that creates a problem for us, right? You don’t know what questions to ask. So we go into the doctor and the doctor tells us you have cancer and we’re going to swoop you in. And in the next two weeks, you’re going to be doing chemotherapy and radiation. And six months from now, we’re going to be doing surgery and there’s no time for questions and you’re scared shitless and you’re just doing what you can to survive. And I get that. And I totally understand that. And I appreciate that. But I’m telling you that If that is your choice, that is your choice. But as you’re doing that, take the time to ask the right questions. When this happened to us, there was a lot of challenging things with the oncology team. Nobody bothered to allow them to be a partner in their care. They dictated their care, but didn’t allow them to be a partner. So, Dr. Deb Muth 08:17Here’s what most oncologists do when patients get a cancer diagnosis. They look at the tumor type, they look at the stage, they look up the NCC guidelines, the National Comprehensive Cancer Network, and they follow the algorithm. Now, I have an enormous respect for conventional oncology. I really do. Working with cancer is probably one of the hardest things in medicine that anyone can do. The advances in this field over the last 10 years have been remarkable. But here’s my issue. Standard treatment assumes your cancer is the same as the cancer in the clinical trial that created the guidelines. It’s assuming that you and your cancer are the exact same as everyone else. You are the unique fingerprint, not the cancer. And this is the problem because your cancer is unique, just as unique as if you had your fingerprint taken, the mutations driving your tumor, the drugs your cancer cells are sensitive to, the metabolic vulnerabilities of your cancer. These are all different from the person sitting next to you in the chemo suite that has the same triple negative breast cancer or HER2 positive breast cancer or prostate cancer or colon cancer that you have. So what do do about that? Well, in my world, in the integrative medicine world, we test precisely, intelligently with the tools that most oncologists have never heard of. Or if they have, they haven’t incorporated it into their treatment modality for a variety of reasons. Either it’s not acceptable by the organization that they work for, they don’t understand it, They’re not going to be able to change their protocol anyway because they have to follow the NCCN protocol. So they don’t do it or they use a portion of it and they don’t do anything outside the protocol. So today I want to cover three things with you, three tools that we used that I think every cancer patient should be asking for when they start treatment or wherever you are in treatment at this point. Dr. Deb Muth 10:44you need to have these tests done. I don’t have any affiliation with any of these companies. I don’t get paid to tell you any of this. So let me just start by saying that I understand the chemistry behind these and how important it is to give you precision cancer treatment. And that’s why I’m talking about them today. The first one we’re going to talk about is the North Star response. This is your cancer surveillance score in the blood. How much cancer is circulating in the blood. The North Star Select, your cancer’s genomic blueprint from a blood draw. And the Datar Cancer Genetic Chemoscale, the live cell drug sensitivity test that tells us which drugs actually kill your cancer. So let’s go. Let’s dive into this. Let me just take a drink here. I’m going to cough a little bit. I apologize. I have this horrible tickle. It just never seems to go away, but that is not for today to discuss. So what is all of this? OK, the North Star response is a test that was developed by a company called Billion to One. And yes, that name is intentional because of the precision involved. It’s a next generation sequencing test, meaning it reads DNA at an incredibly detailed level. And it looks at something called methylated circulating tumor DNA or methylated CT DNA. Now let me break this down in plain English for you, because this can get a little overwhelming. When the cancer cells die or shed, they release tiny fragments of DNA into your bloodstream. We call this cell-free DNA or CFDNA, and it’s hidden within that cell-free DNA. And there are fragments that come from tumor cells. We call those CT DNA or circulating tumor DNA. Here’s what makes North Star’s response different. Rather than just looking for mutations in that tumor DNA, which is what most liquid biopsies do, and a liquid biopsy is just a blood test, Dr. Deb Muth 13:03This test looks at something called methylation patterns. Think of methylation like a dimmer switch on a gene. In healthy cells, certain genes are switched on and off in a very predictable way. In cancer cells, those dimmer switches go haywire. And cancer DNA has a characteristic hypermethylation, meaning switches are turning on and should be off or off and they should be on. And these patterns are essentially a cancer fingerprint in the blood. Now the North Star response scans more than 2000 locations in the genome for these cancer specific methylation patterns. And then it adds them all up into a single number called the tumor methylation score or TMS. So for Cameron, Cameron’s blood which was drawn on April 20th, 2026, his baseline tumor methylation score came back at 13. Now here’s the critical thing, to understand this was his baseline test, his starting point. And the real power of this test is in serial monitoring, meaning we run it again and again and again over time. And if that number goes up, the cancer activity is likely increasing. If it goes down, we’re likely suppressing the tumor activity. And if it stays flat or falls, that’s telling us that the disease is responding. So this is now in the blood. We have an actual fingerprint and every test from here forward will be compared to this number. Now let’s talk a little bit about this because I was not familiar with this test at all. I wasn’t sure what to expect. I wasn’t sure what to do with it. I did not order this test. He’s working with Inveda Medical and they are fabulous over there. I will tell you that from the beginning. This is coming from a practitioner and from a mother-in-law. They were absolutely wonderful to us. So when I saw this North Star, I didn’t know, should it be zero? Should it be a hundred? And when I talked to the doctor, he said, Dr. Deb Muth 15:29This number is actually really good. An average person walking around who’s never been diagnosed with cancer, who doesn’t have cancer, their number will be between 75 and 100. Cameron’s was 13. I think that’s fantastic. But what was the first question that went through my head? It’s probably the same question that you guys are doing. How can he have cancer with a number of 13 when it’s less than the normal average? And if we’re supposed to use this to track what’s happening with his cancer, how are we going to do that once we remove the cancer? Is this number going to go to zero? And it could possibly do that. And we may not be able to use this to track whether or not the disease is actually gone. But what we can do is use this to track over the course of his lifetime to see if the cancer cells are coming back long before we detect them on imaging. And that’s the huge part of this.So this is not a test that just anybody should go out and get because you’re worried about cancer. It is a test that should be done in somebody that is already diagnosed with cancer. So let’s start by making sure we explain that, okay? So imagine if every time your cancer cells are active and they’re shedding and they’re multiplying and they’re fighting back, they’re leaving a signature in your blood not just any signature, but a specific chemical tag that says, cancer’s here. That’s what the North Star Response Test reads. Those tags across thousands of locations and gives us a single score. So we track that score over time like a thermometer for your tumor. If it goes up, we get concerned. If it stays stable or goes down, we celebrate. And we can catch a change in the blood often months before it will show up on a scan. Pretty important when we’re talking about surveilling somebody for cancer returning, when we’re worried about it, and everybody knows the cancer patient is always worried after they get that clean bill health that something’s gonna come back, and most of the time they’re told that there is no way for them to determine that or know that from a blood test. And here is the blood test that can tell us, yes, it can. Dr. Deb Muth 17:51So I would really encourage you guys to talk to your oncologist about this. If you can’t find an oncologist that will do this, talk to an integrative cancer doctor. They will most likely be familiar with it. If not, ask them to find it for you and order it for you. So next, let’s talk about that genetic blueprint because North Star Select is a different test also by billion to one run on the same blood draw, but this one is doing something completely different. This is a comprehensive genomic liquid biopsy. Liquid biopsy just means blood tusks, meaning it’s looking for specific mutations in 84 cancer related genes, all from a blood sample, no biopsy needle, no surgery, just a blood draw. It looks for CNVS, single nucleotide variants, tiny one-letter typos in the DNA code. It looks for indels, small insertions or deletions in the DNA. It looks for copy number changes, the sections of the genomes that are duplicated or deleted. It looks at fusions. So when two genes incorrectly link together to create a dangerous hybrid, MSI status, micro satellite instability, which tells us whether immunotherapy is likely to work. And it has extraordinary sensitivity. It can detect a mutation that represents as little as 0.15 % of cell free DNA in the bloodstream. That is an almost impossibly small signal in the ocean of genetic noise. So what did this show for Cameron? This is where Cameron’s case gets clinically fascinating and where it tells the story of how his cancer is being held in check. Two major mutations were identified as actionable. One was called CRAS G12C. Dr. Deb Muth 20:11And it’s a variant-ELI fraction at 0.1%. Now, CRAS, if you’ve spent any time in integrative oncology, you’ve heard this name. CRAS is one of the most well-known oncogenes in cancer biology. Think of it like an accelerator pedal in the car. In a healthy cell, CRAS pushes the cell to grow when it receives the signal to do so. And then it stops. In cancer, crass gets stuck in the go position, like on the accelerator, foot on the accelerator, to the floor, going as fast as you can around that track, right? But it’s stuck there permanently. It doesn’t turn off and it’s supposed to be turning off. The G12C variant specifically is a mutation at a very precise location. Position 12 of the CRAS protein, where a glycine is replaced by cysteine. And this matters because CRAS G12C is now a drugable target. There are FDA approved drugs specifically designed to lock this mutation into its inactive state, essentially putting a foot on the brake. Now those are drugs like, and I’m gonna slaughter these names, Sordisib, a brand name is Lumacras, and Atacras, the brand name is Crastol. Neither is yet FDA approved for breast cancer, but they are approved for lung and colorectal cancer with CrasG2C. And Cameron’s tests identified 10 active clinical trials within a region that he could potentially qualify for with this mutation. The fact that his CRAS G12C is circulating at only 0.1%. That is a very low fraction. We call that a VAF, V-A-F, very low fraction. And it tells us something important. It means that this mutation is present in a small subclone of the tumor. It’s not the overall tumor burden. So either way, when we identify, we know it’s there. Dr. Deb Muth 22:37We can catch it and we can watch it. Now, here’s another interesting thing that we saw. His TP53 was at 0.23%. This is a tumor suppressor gene, the guardian of genome. And this gene is responsible for telling damaged cells to either repair themselves or self-destruct. And when it mutates as it is here in the position R196Q, that guardian goes off duty. The cell no longer has a reliable mechanism to prevent uncontrolled growth. So TP53 mutations are present in roughly 50 % of all human cancers. And there’s currently no FDA approved drug directly targeting the TP53 but there are clinical implications. TP53 mutant tumors may respond differently to chemotherapy and several investigational approaches, including TP53 vaccines and aurora kinase inhibitors are under active investigation. So we are seeing things happen in this part of cancer right now. Now there’s something called the VUS list and we are watching This is what we’re watching. beyond those two actionable mutations, NORSTAR Select identified what we call variants of an unknown significance, VUS, adenocarcinoma of an unknown significance, ACUP. These are mutations where we don’t yet have enough clinical evidence to determine whether they’re driving cancer or not, but we watch them. So on our mutation list was CDH1, a gene linked to hereditary gastric and lobular breast cancer, CDKN2A, a tumor suppressor cell cycle regulator, CDK12, involved in DNA repair, EGFR, ERBB, this is HER2 receptor, tyrosine kinases. Dr. Deb Muth 24:55I thought this one was pretty interesting since he had an IHC that showed a three plus HER2, but then when we confirmed it with FISH, FISH showed that was negative, but now we’re actually seeing genes expressing this HER2. So is there a HER2? Is there not a HER2? This is really important because if we don’t get these diagnoses right in cancer the first time, people will spend months and years treating the wrong type of cancer with the wrong type of medication. And this may be in part why some people do better than others. If we get it right out of the gate, they do good. If we don’t get it right out of the gate, they don’t do so good. Very important to have the actual genetic makeup of the tumor that’s growing in somebody. Now last, we have something called Notch C1, NRAS and RAF1. These are key pathway components. Now all of these were at very low baffs under 0.5%. These are just whispers, not shouts, but whispers that this cancer is excreting, but your body is listening. We have to be listening. We have to be able to watch these things and monitor these. Now here’s another note of clinical interest. It was an androgen receptor positive cancer. So also detected as a VUS.We know from tissue pathology that Cameron’s tumor was androgen receptor positive. So seeing this in circulation confirms that this AR expression of the cells are present in the bloodstream and that an anti-androgen approach remains worth considering. What that means is suppressing the testosterone. What all of you know I’m about ready to say is that I hate ever suppressing hormones, especially in a 38 year old male. That is not necessarily a good thing. So before we go suppressing hormones willy-nilly, we have to know that it’s the right thing to do. And we have to be able to combat all of the complications that are going to result of that. A 38-year-old male with no testosterone could lead to heart disease down the road, could lead to bone loss, could lead to dementia, Alzheimer’s. Not to mention the sexual side effects that are going to be present. And in a man that is very, very Dr. Deb Muth 27:20Difficult for someone to manage. So you have to be very specific and you want to be very, very diligent about what you’re doing in these cases like this. Now the MSI status was not detected. This tells us that cancer is not a microsatellite instability high, meaning that standard monotherapy may have a lower baseline response of probability and the strategic integration that we’re working with with in Vita could create an immunogenesis genicity becomes even more critical. So immunotherapy is going to be very critical in a cancer case like this and working with somebody that understands that and can carefully navigate that, especially if you have an autoimmune disease like Hashimoto’s or lupus, this is all very, very pristine and has to be looked at very carefully and done very diligently in order for somebody to do this without overstimulating that immune system and causing more problems. So when we looked at the blood and found this DNA fingerprint of the cancer cells circulating in the body, from that, what we see exactly is the genetic switches that are stuck on. They’re stuck on in the wrong position. This tells us which drugs were designed to fix exactly that problem. And it opens the door to clinical trials built for these specific mutations. It also gives us a list of things to watch for over time. And if one of those tiny little signals starts to grow, we know that cancer is gaining a ground in that area. And if it shrinks or disappears, we know we’re winning. This is like, I cannot tell you how exciting this is in the cancer world and the medical world because this is really pristine cancer therapy that we’re dealing with here. And to be able to have this is just so important to life saving events in treating cancer. So. Dr. Deb Muth 29:41Let’s talk about something called the Dittar Chemoscale. This is the battle before the battle. Okay, so I’ve saved the most remarkable test for last, and this is one from a company called Dittar Cancer Genetics. They’re based out of the UK. They are CAP and CLIA certified, which means it meets the rigorous standards required for clinical laboratory testing in the US. And this test is called the ChemoScale. And it is a live cell chemosensitivity assay. So let me explain exactly what that means because it sounds complex, but the concept is actually quite elegant. When we drew the blood from Cameron, the Dittar’s laboratory isolated what are called circulating tumor associated cells or CTACs. And these are actually living cancer cells and they’re associated cells that are traveling through his bloodstream. Excuse me. So let’s think about that for a moment. Real live cancer cells isolated from a blood draw. Those living cancer cells were placed into a lab environment and exposed to over 70 different drugs, both conventional chemotherapy agents and what we call repurposed drugs. I’ll talk more about those in a minute. The lab then measured how many of those cancer cells were killed by each drug expressed as a percentage of cell death. So the scale runs from zero to a hundred and below 25%, that drug doesn’t work well against any type of cancer in that person. Might work great in somebody else, but in that particular person’s cancer that they have, it’s not gonna work so great. Anything that’s 25 to 50 % is intermediate and above 50 % is a high response. And that’s really where Dr. Deb Muth 31:43we want to be. We want to see anything higher than 50 % because that’s a great medication that can be used to kill the cancer. This is not a theoretical test. This is not based on tumor’s genetic sequence and the computer algorithm that predicts the drug response. This is a HIS actual tumor cell being killed or not being killed in real time. That is the difference. So in traditional chemotherapy, we have our protocols. If you have triple negative breast cancer, if you have HER2 positive breast cancer, if you have prostate cancer, if you have colon cancer, here’s the protocol that you’re going to use because that’s the type of cancer you have. That’s what’s been studied. Now, the problem is most of these cancers have mutated over time, especially depending on how long they’ve been in your body, because that’s what they do to try to survive. They have to change so they can survive because your immune system’s constantly trying to kill them. And so this is a really important thing. And if we don’t take an individual into response or into our thought process when we’re creating these protocols, we may give a drug that doesn’t work at all towards that cancer and you just wasted seven cycles of chemotherapy with a drug that never would have worked in the first place or had such low resistance to it that it’s now just created side effects for you but did nothing to the cancer. And then we pull out another drug and we try that. And then we pull out another drug and we try that. Instead of us knowing precisely what we can use and what we can do. And this goes for both the conventional world and the alternative world. In the alternative world of cancer, we use things like IV vitamin C and tumeric and lately ivermectin and fenbendazole and mendendazole and all kinds of other things. And if we are not truly aware that this is going to do anything, we could be wasting somebody’s time and money. So I love that this test is available. I want to walk you through a little bit about what Dr. Deb Muth 34:01we are what we saw in our case, because I think this can make a big impact on people to ask the right questions. So this particular blood test looked at several different drugs. Cameron had sensitivity from 44 % up to 61 % on different medications. Now he was really lucky. The three main drugs that they would use to treat his cancer he had greater than a 50 % response to. So that was great. However, the drugs that were recommended for him to use out of the gate had less than 50 % activity. So he would have had one drug that was really good, one drug that was not so good. And we don’t know what the outcome would have been, right? So I think this is such an incredible, incredible test to have done. This is critical friends. I’m telling you if his oncologist had chosen the two drugs based on the general guidelines for his tumor, his cells would have largely not survived. But because we ran this test, we know. So we know to avoid the drugs that won’t work and we focus on the firepower where it really counts. So I want to also talk about this repurposed drug result because this is where it gets integrated for us. Now, this section is what I want everyone in our community, our Let’s Talk Wellness community, our members to understand. This is where conventional medicine and integrative medicine intersect in a peer-reviewed clinical validated way. So the Dittar test looks at live cancer cells against what they call repurposed drugs, meaning pharmaceuticals and natural compounds that were developed for the purposes, for other purposes, like it could be an antibiotic, it could be an herbal medicine, it could be all kinds of things, vitamins, whatever. But they have demonstrated anti-cancer activity in research. And when we’re talking about integrative medicine, this is a lot of where we get Dr. Deb Muth 36:26The integrative protocols from because these particular drug compounds are known for having anti-cancer benefits. And so that’s how integrative protocols get developed. But again, it could be just like medication, like cancer drugs. If your body doesn’t have a susceptibility to it, then you’re using a product that’s not necessarily going to work. And we all know we cannot take everything that somebody recommends just simply because it has an anti-benefit to whatever it is we’re treating. There’s only so many supplements you can take. There’s only so many things you can do before you get burnt out on taking it. We call it supplement fatigue. And so we want to be very precise with what we’re doing and target this very specific area. So one of the things that showed up really, really well for our case was artemisium, sweet wormwood. It’s an anti-malarial drug that has very potent anti-cancer effects. Now I found this extremely interesting in Cameron’s case because he does have a positive tick-borne illness called Babesia. And this is one of the things that we use to treat Babesia. The other thing I think is very interesting in this case is we are studying how parasites affect cancer these days. And that’s how Ivermectin, Fenbendazole, and Menbendazole have all gotten thrown into the treatment of cancer. And so for this drug or this herb to be sensitive to this type of cancer is really intriguing to me in the world of parasites and how parasites are truly decreasing the body’s immune system and causing cancer to grow. Another thing that worked, showed up really well for him was Valprolac acid. It’s an anti-seizure drug with HDAC inhibitor properties, and this disrupts cancer cell gene expression. There was a soy formula that showed up really well. Naltrexone, you guys have heard me talk about low dose naltrexone, LDN. This actually stimulates an endogenous opioid immune response feeling, and this drug actually showed up really well. Dr. Deb Muth 38:49Something as simple as quercetin. It’s an anti-inflammatory. This is a crass inhibitor in some studies. So this is really important. I’m sure most of you have heard about the benefits of green tea and green tea also actually has anti-angiogenic or anti-cancer benefits to it. Hydroxychloroquine, very popular drug. It’s another anti-malarial drug. So again, now we have two anti-malarial drugs that are susceptible to this type of cancer. And on top of it, he has a positive babesia test. So just saying, you got to connect the dots sometimes. You got to think outside the box sometimes. Metformin is very well known as a anti-proliferative in cancer. We use it to suppress the sugar because sugar feeds cancer. Nobody should be eating sugar if they have cancer. So this one showed up as well. And then CBD, we all know of the benefits of THC, the Rick Simpson oil, and CBD can be tested to see if that is beneficial to a particular cancer cell. This is different than THC. THC works very differently in cancer. CBD is your healthy component of it. It’s the part of the marijuana plant that does not make you high. So very important here. So now let me be very clear, because I always try to be very clear. This is not FDA approved. I’m going to repeat that. This is not FDA approved. This test is a laboratory developed test, not FDA cleared. These results represent in vitro testing, meaning in a lab, not inside the human body. And the results can differ in what we call in vivo, inside the body. And this is why I always say work with a qualified clinician who can interpret these results in full clinical context. But here’s why this matters. We now have evidence, live evidence of a cancer cell that shows sensitivities to compounds that are accessible, relatively safe, and some of which he may already be using, which some of them we were. Dr. Deb Muth 41:13We were already using some of them, which made us sit back and say, this cancer has been in there for two years. If it’s a triple negative breast cancer, it’s supposed to be an aggressive breast cancer that should have spread to a different organ already after two years. It is not, it has stayed in one spot. Also interesting in this case is that there is no breast tumor that they could find anywhere. This was all confined to the axilla into the lymph node. So to have this growing for this period of time with such a small tumor marker number, that 13 that we talked about in the North Star test originally, and to see some mutations, there’s a lot of questions to this particular case. And there are lots of questions to everybody’s cancer case. They are not all straightforward cancer cases. So this is what’s important to understand this fingerprint of these cancer cells so that you can identify exactly, exactly what’s going on and treat it exactly the correct way. Super important. So this kind of information gives us the direction in an integrative protocol. It’s not guessing. This is not eat more tumor, I can hope for the best. This is personalized tumor specific precision guided integrative oncology. It is very precise. There are several countries, several clinics like this around the country that offer this type of therapy. If it’s something that you’re interested in doing, I would encourage you to look at in Vita Medical. Hope for Cancer is another great facility. There are several great facilities around the country. Like I said, that could put together an integrative approach for you if this is something that you are thinking about doing. If you’re looking for answers, if you’re in stage four or stage three and you are not getting the results that you want to get, you want to look at a different approach. You want to do a combo approach of integrative medicine and traditional medicine and alternative medicine. Dr. Deb Muth 43:37I think this is so important to look at and have experts on your team. You know, in our case, Cameron’s cancer is very complex. It’s genomically aggressive in its presentation, yet it’s not progressing to distant areas, which is so wonderful. And I want to be careful here. I can’t tell you with certainty that this is any one thing. Biology is complex. Cancer is adaptive. It’s trying to survive. That’s what it is supposed to do. It is changing its shape. It’s changing its genetic structure. It’s changing everything to try to survive and try to hide against your immune system. Now we are not even close to the finish line in our journey, but what I can tell you is that what the integrative precision approach has done that standard care alone might not do. I can tell you that today and I will share our journey along the way for any of you that are going through this that want to look at a different approach as well because I think it’s important to have this information. So first of all, we know the tumor’s fingerprint. North Star response gives us that TMS score. so we can track it over time. And if the cancer tries to gain ground, we’ll see it in the blood before a scan, we’ll show it. We know the cancer’s genetic vulnerability. We know how to handle the DNA now. We know the watch list of things to look for. And when those signals start to grow, we have a roadmap of how to address it next, how to change it. We know which drugs will automatically work against the tumor cells. We’re not guessing based on a tumor type. We tested the cells. We know how many drugs in the commercial world and in the repurposed world will and will not work. And this is going to guide the treatment protocol that we walk forward with. So we’re not giving him drugs that won’t work or have a low response. Dr. Deb Muth 45:55We’re avoiding them completely and that matters because every ineffective drug is a dose of toxicity with no benefit. There is no lie to this. Chemotherapeutic drugs are toxic. That’s how they kill the cells, but they kill the good cells and the bad cells. And if we can avoid using a drug that’s not going to work, that is so important. And then we’re layering in those repurposed and natural compounds with proven activity against specific cells. This is not complementary fluff. This is biologically active tumor tested precision medicine. Very, very important. So here is what I need you all to know and what I want you to walk away with today. If you or someone you love is facing a cancer diagnosis before treatment starts, before the first infusion goes in, I want you to ask these questions so quick. Go grab something to write with. Pause this if you need to, because this is really, really important for you to do that. And we’re going to take a break for just a second while you guys go and do that. We’re going to give you a word from our sponsor, and then we’re going to come back. And I’m going to give you the four questions that I want you to ask specifically of your medical team so that you have the answers and the ammunition that you need to work with. So we’ll be right back. Dr. Deb Muth 47:29All right, everybody, welcome back. I hope you got your pencil, your paper, your pen, your phone, whatever you’re going to take notes with because this is important. So I’m to give you four questions that I want you to ask your medical team before you get started. Question one, can we do a chemo sensitivity test before we choose a chemotherapy regime? Ask specifically about DATAR, D-A-T-A-R. cancer genetics, Oncostat Plus, or a similar functional chemosensitivity platform. Very, very important to ask those specific things. All right, question two. Can we do a comprehensive liquid biopsy to identify actionable mutations and monitor tumor burden? Ask about North Star Select, Billion to One, Guardian 360, or Foundation One Liquid CDX? I’m gonna say those for you one more time, because I said them kind of fast. North Star Select by Billion to One, Guardian 360 or Foundation One Liquid CDX? Okay, question three. Can we establish a baseline tumor methylation score, TMS, so we have a surveillance marker to track over time? and ask specifically about the North Star Response Test. All right, question four. Is there an integrative oncology center that can layer precision guided natural compounds alongside conventional treatment? Research institutes like Inveda Medical Center, CTA CA Integrative Medicine, or Hope for Cancer, these people are doing integrative medical miracles. Let me tell you, I have researched every one of them. I have spoken to each of them individually before we made our decision of who we were going to work with. They are all fantastic. You want to work with an integrative nurse practitioner who understands oncology. And if you’re working with an integrative practitioner, you want to ask them these same questions about this test so that you can get the best outcome. Dr. Deb Muth 49:56For what you’re dealing with. You are allowed to ask these questions. You are allowed to want more information from that protocol that was designed for the average patient. You’re not average and your cancer is not average either. And your care doesn’t have to be. You do not have to settle for the same thing that the person sitting next to you in the IV suite is dealing with when you both have different cancers excreting different genetic material. This is so incredibly important. want to make sure you understand precision medicine is what changes the lives for people every single day, every single day. So I started this episode by telling you about a 38 year old man with a cancer that baffled conventional medicine and integrative medicine, an occult primary that was not found complex genetic genomic profile, a presentation that in many hands might have resulted in a one size fits all treatment protocol and a prayer. And instead we ran the tests, we mapped the fingerprint, we watched the cells, we guided the protocol, and we are still fighting with precision, with data, with intelligence. This is what Let’s Talk Wellness is all about not giving up. This is what not accepting we don’t know as a final answer and demanding the level of scrutiny and personalization that every cancer patient deserves. So if this episode resonates with you, please share it because somewhere out there, there is a person who is about to get the wrong chemotherapy because no one ran the right test. And maybe, just maybe, that This episode will be the reason someone asks the right question at the right moment. If you’re going through something like this, you need a group, you need somebody to connect with, please join our free Facebook group called Seen At Last. It is where we support one another, we share this information, we share knowledge, and we help people for free support and ask the right questions. Dr. Deb Muth 52:23And if you’re inclined in your heart to pray, pray for Cameron, we could use every ounce of prayer. If you are in a position where you can help support this journey financially, we do have a fund going in free funder. I can post the link below. Every little bit helps. If you have $5, $500, it doesn’t matter. We’re raising money for this treatment. And along the way, I am documenting every step of what we’re going through so I can provide more episodes like this for you guys to share the outcome and share what our journey is like so that it can help the next person along. I really always believe that whatever happens to us happens to us because we’re meant to share it. That’s why I’ve shared my personal journey. I’m sharing his personal journey and we want to help other people. So until next time, I’m Dr. Deb. Keep asking questions, keep advocating, and never ever accept being unseen.The post Episode 274 – Stop Guessing on Chemotherapy: The Live Cell Test Most Doctors Miss first appeared on Let's Talk Wellness Now.

L'industrie du vélo européenne a-t-elle encore un avenir face à la domination asiatique ? Claudio Marra, VP mondial de FSA/Vision et figure de l'industrie depuis plus de 20 ans, nous livre son analyse sans filtre.Dans cet épisode, Claudio Marra revient sur les raisons qui ont poussé la production vélo vers l'Asie, les conséquences pour les fabricants européens, et ce que l'avenir réserve à notre industrie. Un regard unique, entre Italie et Taïwan, d'un homme qui a vécu cette transformation de l'intérieur.

Le projet franco-germano-espagnol d'avion de combat du futur est officiellement abandonné. Lancé en 2017 avec l'ambition de renforcer la souveraineté européenne, le SCAF devait succéder au Rafale et à l'Eurofighter. Huit ans plus tard, les rivalités industrielles et les divergences stratégiques ont eu raison du programme.

Send us Fan MailThe clinical trial system is starting to look like a motorway at a standstill: more and more drugs are lining up, but the lanes ahead are already full. We sit down with Pamela Tenart to unpack why the industry may have reached the limit of human-only clinical development, and why “adding more people” is no longer a realistic plan when experienced CRAs, site co-ordinators and trial operators are already stretched thin.From there, we get practical about what agentic AI could change inside clinical trial operations. We talk about AI agents that can pull context across CTMS, EDC, safety reporting and TMF, helping monitors prepare for site visits, flag missing fields, propose next best actions, draft communications, and reduce the dead time where teams are simply waiting for updates. The point is not to automate judgement, but to automate the admin and co-ordination work so humans can focus on strategy, enrolment, quality, and patient safety with a clear audit trail and human-in-the-loop control.We also zoom out to the bigger bottleneck: sponsors, CROs and sites are part of one connected system, so optimising one party can just shift the pain elsewhere. Along the way we explore why better, more sensitive endpoints can shorten trial timelines, how policy and regulation might need to evolve, and a memorable metaphor from industrial history: electricity boosted individual productivity first, but factories only truly improved once they were rebuilt for the new technology.If you're working in clinical research, drug development, biotech, or health tech, this conversation will help you think more clearly about where AI genuinely shortens the critical path and where it simply adds noise. Subscribe, share the episode with a colleague, and leave us a review. Which clinical trial workflow would you redesign first?Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn pageVisit www.labtolives.com HostsAlexander Booth aka the MedTech GuyDimitri Borisevich aka the start-up GuyIvanna Rosendal aka the R&D pharma Gal

In this episode of the Syneos Health Podcast: Site Realities series, host Tammy D'Lugin-Monroe and Audra Holleman, Head, Country Operations, Americas at Syneos Health explore the evolving role of the clinical research associate (CRA)—and why it matters more than ever. From shifting expectations around site relationships to the growing impact of technology and AI, the conversation highlights how CRAs are moving beyond transactional monitoring to become trusted partners, problem solvers and scientific advisors. Together, they unpack what sites and customers value most—responsiveness, continuity and deep expertise—and how an outcomes-based approach is reshaping CRA success. The episode also looks ahead, examining how innovation is freeing CRAs to focus on what drives real impact: strengthening site partnerships, improving patient experiences and accelerating study delivery.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

L'effondrement des populations d'insectes est un sujet préoccupant. François Turrian nous présente une expérience de science participative découverte via une application: "Bugs Matter". En comptabilisant les insectes écrasés sur vos plaques minéralogiques, vous participez à une vaste action de science participative.

Abertura dos trabalhos na Amorosidade

durée : 02:29:08 - par : Gabrielle Oliveira Guyon - Au programme ce samedi : Heitor Villa-Lobos, George Bizet, Klaus Mäkelä, ou encore La java des hommes grenouilles de Ricet Barrier. - réalisation : Emmanuel Benito, Delphine Keravec, Geneviève Cras, Jeanne Lerch Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:27:57 - par : Gabrielle Oliveira Guyon - Au programme ce samedi : Nous écoutons Légende de Louis Vierne puis Félix, 5 ans, de Saint-Etienne nous invite à écouter Pierre et le Loup, et dans le Labo musical de Nico, une nouvelle question se pose : Quelle musique pour la Victoire de Samothrace au Louvre ? - réalisation : Emmanuel Benito, Delphine Keravec, Geneviève Cras, Jeanne Lerch Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:03:04 - Tragique accident de bus à Lourdes - Un Italien de 55 ans est mort dimanche soir, écrasé par le car qu'il avait garé sur un parking à Lourdes. L'hypothèse d'un problème de frein est évoquée. Des employés de l'hôtel où il logeait chaque année racontent leur choc, comme les voisins du parking : "on a entendu un grand boum". Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

O mercado de crédito privado cresceu rapidamente no Brasil nos últimos anos, alcançando cerca de R$ 1,9 trilhão em estoque até janeiro, segundo dados da Anbima. Ao mesmo tempo, eventos recentes, como recuperações judiciais e o aumento da incerteza global com a guerra no Oriente Médio, levantaram dúvidas sobre os riscos dessa classe de ativos, que inclui debêntures, CRIs e CRAs.Neste episódio do Itaú Views, discutimos o que está por trás desse movimento e como interpretar o cenário atual: o que é ruído de curto prazo e o que realmente importa para o investidor?Fayga Delbem, sócia e superintendente de crédito core da Itaú Asset, e Lucas Queiroz, chefe de pesquisa em renda fixa do Itaú BBA, explicam como funciona o mercado de crédito privado, o papel da liquidez, os riscos envolvidos e as principais formas de análise.A conversa também aborda o impacto da taxa de juros, o comportamento dos spreads, os efeitos do cenário macro e as oportunidades que podem surgir em momentos de maior volatilidade.Moderação: Marcelle Gutierrez, Research do Itaú BBA. EmailInstagramTelegramYoutube

durée : 00:09:58 - Journal de 9h - Le pilote américain porté disparu en Iran est sain et sauf. Annonce de Donald Trump sur son réseau social, qui a donné 48 heures à l'Iran hier pour accepter un accord ou le déblocage du détroit d'Ormuz. Ultimatum rejeté par Téhéran qui a de nouveau attaqué dans la nuit les pays du Golfe et Israël.

durée : 00:15:26 - Journal de 12h30 - Son avion de chasse a été abattu vendredi par l'armée iranienne dans le sud-ouest du pays. Téhéran promet une prime pour sa capture alors que le second occupant de l'appareil a pu être secouru et exfiltré au cours d'un raid des forces spéciales américaines. - invités : Julien Talpin Sociologue, directeur de recherche au CNRS

durée : 00:15:26 - Journal de 12h30 - Son avion de chasse a été abattu vendredi par l'armée iranienne dans le sud-ouest du pays. Téhéran promet une prime pour sa capture alors que le second occupant de l'appareil a pu être secouru et exfiltré au cours d'un raid des forces spéciales américaines. - invités : Julien Talpin Sociologue, directeur de recherche au CNRS

Dana Kudrnova from Novotech shares proven strategies to accelerate study startup by overcoming regulatory and administrative bottlenecks. Learn how data-driven KPIs, mandatory templates, and unified technology transform unpredictable timelines into streamlined milestones. Dana emphasizes that while AI provides speed, active ownership and human oversight are what truly prevent document delays. This episode highlights why proactive communication between CRAs and sites is the secret to surfacing issues early and moving from site selection to first patient dosed more efficiently.

No Arauto Repórter UNISC de hoje, você confere:* 24ª Expoagro Afubra tem início com destaque para resiliência no campo e protagonismo do agronegócio* Santa Cruz lança 1ª Osterfest com programação voltada à cultura e família* Iniciativa aproxima Cras dos trabalhadores de Santa Cruz que buscam emprego* Em destaque na segurança pública: Foragido da Justiça de Curitiba é localizado e preso em Santa Cruz

No Arauto Repórter UNISC de hoje, você confere:* 24ª Expoagro Afubra tem início com destaque para resiliência no campo e protagonismo do agronegócio* Santa Cruz lança 1ª Osterfest com programação voltada à cultura e família* Iniciativa aproxima Cras dos trabalhadores de Santa Cruz que buscam emprego* Em destaque na segurança pública: Foragido da Justiça de Curitiba é localizado e preso em Santa Cruz

Son nom m'avait été soufflé par un grand vigneron bourguignon. J'ai d'abord goûté sa « Montagne de Cras 382 », un Chardonnay 100 %, et cette dégustation m'a immédiatement donné envie de le rencontrer.Champenois d'origine, Boris Champy étudie en Champagne puis à Bordeaux. Son parcours le mène ensuite en Californie, où il travaille pendant dix ans chez Dominus Estate, propriété de la famille Moueix, figure emblématique de la rive droite bordelaise (propriétaire de Petrus entre autres). De retour en Bourgogne, il devient Directeur Technique de Louis Latour au cœur du domaine d'Aloxe-Corton durant neuf ans, avant de prendre la direction du Clos des Lambrays à Morey-Saint-Denis.En 2019, il rencontre Didier Montchovet, pionnier de la biodynamie dès les années 1980 dans les Hautes-Côtes de Beaune. À la recherche d'un repreneur pour prolonger l'esprit familial de son domaine, Didier trouve en Boris un successeur naturel. La transmission se fait à quatre mains lors des vendanges 2019.Dans cet entretien, nous évoquons la beauté exceptionnelle du site — classé Natura 2000 — refuge de nombreuses espèces d'oiseaux, dont le Circaète Jean-le-Blanc. Nous parlons également des cépages, des choix de vinification, de l'élevage, autour d'une dégustation de quatre cuvées emblématiques du domaine.

Pour en savoir plus sur comment trouver le bonheur et remplir ta vie d'épanouissement, je te donne rendez-vous sur : https://www.sylvainviens.com/Tu as parfois l'impression de manquer d'air dans ta propre vie ? Comme si tout reposait sur tes épaules, comme si tu étais en permanence sous pression ?Dans cet épisode, je t'aide à comprendre pourquoi tu te sens écrasé(e)… et surtout comment retrouver de la légèreté, du souffle et de l'alignement.On explore ensemble les 5 vrais ennemis de la légèreté intérieure :• Ton dialogue interne : cette petite voix qui te met la pression, te critique, te culpabilise et t'empêche de te reposer• Le besoin de tout gérer : tout organiser, tout anticiper, tout contrôler… jusqu'à t'épuiser• La méconnaissance de toi : continuer à dire oui à des choses qui ne te nourrissent pas, loin de tes valeurs• Le mental en boucle : “tu aurais dû”, “tu dois”, “tu n'en fais pas assez”… ce bruit constant qui t'empêche d'être présent(e)• Certaines relations : celles qui te plombent, te vident, et demandent de poser des limites pour protéger ton énergieAvec des exemples concrets, mon vécu (la pression, l'asphyxie en entreprise, la recherche d'alignement) et des clés applicables tout de suite, tu vas apprendre à :✔ Transformer ton dialogue intérieur✔ Lâcher prise sans abandonner✔ Clarifier tes valeurs profondes✔ Apaiser ton mental✔ Mettre des limites saines dans tes relationsCet épisode parle de lâcher-prise, développement personnel, connaissance de soi, gestion du stress, charge mentale et équilibre de vie.Si tu traverses une période de fatigue émotionnelle, de surcharge mentale ou de perte de sens, il peut devenir un vrai point de départ pour retrouver de l'oxygène intérieur.

La guerra in Ucraina sembra andare verso una pace armata, la tragedia di Cras Montana che si poteva evitare, l'indifferenza dei popoli

Avec : Frédéric Hermel, journaliste RMC. Pierre Rondeau, économiste. Et Yael Mellul, ancienne avocate. - Accompagnée de Charles Magnien et sa bande, Estelle Denis s'invite à la table des français pour traiter des sujets qui font leur quotidien. Société, conso, actualité, débats, coup de gueule, coups de cœurs… En simultané sur RMC Story.

Hur kan skrivandet ersätta missbruket? Kristoffer Cras är författare och manusskribent. Vi pratar om hans stökiga ungdom, vägen till och från heroinmissbruket, kreativitetens natur, hur skrivandet blev det nya beroendet, böckerna som satte honom på kartan, konspirationsteorier, processen bakom böckerna och mycket mer. Följ Kristoffer Cras via @kristoffercras på Instagram, hitta hans böcker som nya Modus Operandi där böcker säljs och hans filmer som Exodus på streamingtjänster.Yoshi's Podcast hittas på Spotify, Apple Podcasts, YouTube och andra poddplattformar. Prenumerera på https://aljosja.substack.com för att få notiser om nya avsnitt, samt på https://yoshisss.substack.com för att följa mitt skrivande. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit aljosja.substack.com

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

In this forward-looking episode, Lynn Hamilton sits down with Bret Couturier, Executive Director, FSP 360 at Syneos Health, to explore how sponsors can shift from incremental improvements to intentional design when it comes to site experience. With a career spanning frontline monitoring to strategic FSP leadership, Bret offers practical insights into what's working, and what's holding teams back. Key themes include:Why the CRA role isn't disappearing, but rather evolving with AI and data-driven toolsThe importance of designing from the site's perspective, not just for internal efficiencyHow functional service provider (FSP) models can go beyond staffing to drive systemic improvementSimple but powerful steps sponsors can take now to reduce burden and build stronger site relationshipsWhat it means to move from reactive fixes to strategic collaboration, and why the time is now If you're rethinking site engagement, functional models or the next phase of FSP delivery, this conversation offers both strategic clarity and real-world takeaways.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Il Morning Show 07 Gennaioi 2026Sostieni anche tu questo programma...dona!https://buy.stripe.com/dR6bJU69Cf7k6WseUU

Risk-based monitoring has been discussed in clinical research for more than a decade, yet many organizations still struggle to implement it in a meaningful and effective way. In this episode of the Clinical Trial Podcast, we sit down with Dr. Artem Andrianov, a leading expert in clinical data quality and risk-based quality management, to unpack what risk-based monitoring really means in today's regulatory landscape.  Artem has over 25 years of experience in the pharmaceutical industry and is the CEO and cofounder of Cyntegrity a company that specializes in data driven risk management in clinical trials. Together, they explore how the industry has evolved from traditional monitoring approaches to a more holistic model centered on risk-based quality management and quality by design.  Dr. Andrianov shares practical insights on common misconceptions, why simply reducing monitoring is not a strategy, and how technology and analytics can be used to proactively manage risk. The conversation also examines the changing role of CRAs, and the growing expectations from regulators and inspectors.   

 8/8 Trauma, Memory, and the Silence of "Eating Bitterness" — Tanya Branigan — Branigan characterizes the CRas a collective convulsion or "Maoist hysteria." Mental health infrastructure was historically underdeveloped in China, and psychology was officially condemned as "bourgeois pseudoscience." The pervasive cultural idiom "eating bitterness" reflects fatalistic endurance of suffering without complaint. Severe trauma fractured survivors' memory systems, producing lasting psychiatric consequences including psychotic episodes and dissociative disorders. The national silence surrounding the CR results from both deliberate state suppression and the widespread personal psychological devastation experienced by millions of survivors. 1967

Triforce Mailbag Special 64! We're bringing back a load of old topics with some feedback mail and Sips has the AUDACITY to ask for FREE STUFF from a HARVEST FESTIVAL?! Go to http://expressvpn.com/triforce today and get an extra 3 months free on a 1-year package! Support your favourite podcast on Patreon: https://bit.ly/2SMnzk6 Music courtesy of Epidemic Sound. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Juros elevados e disputa com o Estado para tomada de crédito inviabilizam CRAs, CDCAs e CPRs

Aujourd'hui, Barbara Lefebvre, professeur d'histoire-géographie, Bruno Poncet, cheminot, et Didier Giraud, agriculteur de Saône-et-Loire, débattent de l'actualité autour d'Alain Marschall et Olivier Truchot.

Goodbye horses. ////Wines////Domaine de la Cras, VDF Blanc, 'L'Aigle et la Chouette," 2022//Julien Guillot/ Domaine Vignes du Maynes, Macon Rouge, 'Cuvee 910,' 2023//Clos Rougeard, Saumur Champigny, 'Le Clos,' 2010////Support the show

durée : 00:06:45 - L'invité de 6h20 - par : Mathilde MUNOS - Le cinéaste Nicolas Philibert, parrain du festival "Cinéma à la folie" et auteur de plusieurs films documentaires en psychiatrie, regrette que, dans ce champ-là, "l'écoute" soit aujourd'hui "un peu écrasée". Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Remco Evenepoel a survolé le contre la montre des Mondiaux. Le belge a écrasé la concurrence pour remporter sa troisième couronne planétaire. On en discute ensemble !Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

- Stellantis Faces Tough Decisions After Losing Billions - China Central Government Takes Over Changan - Waymo Expanding to Dallas - Shanghai Wants 6 Million L4 Cars by 2027 - Cheap Chinese EV Aces Crash Tests - Lexus Dropping V8s and Gaining an EV Supercar - Audi Warns of Used-Car Scam - Opel Astra PHEV Gets More Power and Range - Corvette Hypercar Concept Poll Results

durée : 00:01:36 - Les 80'' - par : Nicolas Demorand - Amélie Perrier prend 80 secondes ce matin pour une escapade BD en Grèce... Peut-être avez-vous la chance d'y passer des vacances cet été ? Mais même si ce n'est pas le cas, elle vous invite à plonger dans "Rébétissa", un magnifique roman graphique signé David Prudhomme. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Charlie Van Zant, former City Manager of Keystone Heights, brings a diverse leadership background from military service and public education to his role in city government. He shares how Keystone Heights effectively leverages its Community Redevelopment Agency (CRA), covering half the city, to support local projects. Charlie offers advice to other city leaders about getting involved with the Florida League of Cities and advocating at the state level to ensure small cities are heard.

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Merci Marie !À découvrir :

Neste episódio do Gestão Rural, recebemos novamente o economista Antônio da Luz para analisar o cenário do agronegócio em 2025. Discutimos a significativa melhora no primeiro semestre deste ano, impulsionada por uma safra recorde e preços mais favoráveis, contrastando com as dificuldades enfrentadas em 2024. Antônio abordou os impactos macroeconômicos, os desafios da infraestrutura e da tributação no Brasil, mas também destacou as enormes oportunidades do agro, especialmente na produção de alimentos e energia renovável. Um dos pontos centrais foi aprofundar a conversa sobre a gestão financeira para o produtor, ressaltando a importância de otimizar o caixa do negócio e diversificar investimentos pessoais para garantir liberdade, paz de espírito e facilitar a continuidade familiar, além de trazer as projeções para o final de 2025, incluindo logística, câmbio e o mercado de milho. PARCEIRO DESTE EPISÓDIO Este episódio foi trazido até você pela SCADIAgro! A SCADIAgro trabalha diariamente com o compromisso de garantir aos produtores rurais as informações que tornem a gestão econômica e fiscal de suas propriedades mais sustentável e eficiente. Com mais de 30 anos no mercado, a empresa desenvolve soluções de gestão para produtores rurais espalhados pelo Brasil através de seu software. SCADIAgro: Simplificando a Gestão para o Produtor Rural Site: https://scadiagro.com.br/Podcast Gestão Rural: https://open.spotify.com/show/7cSnKbi7Ad3bcZV9nExfMi?si=766354cb313f4785Instagram: https://www.instagram.com/scadiagro/LinkedIn: https://www.linkedin.com/company/scadiagroYouTube: https://www.youtube.com/channel/UCQxErIaU0zBkCAmFqkMohcQ INTERAJA COM O AGRO RESENHAInstagram: instagram.com/agroresenhaTwitter: x.com/agroresenhaFacebook: facebook.com/agroresenhaYouTube: youtube.com/agroresenhaCanal do Telegram: https://t.me/agroresenhaCanal do WhatsApp: https://bit.ly/zap-arp-01 E-MAILSe você tem alguma sugestão de pauta, reclamação ou dúvida envie um e-mail para contato@agroresenha.com.br ACOMPANHE A REDE AGROCASTInstagram: instagram.com/redeagrocast/Facebook: facebook.com/redeagrocast/Twitter: x.com/redeagrocast FICHA TÉCNICAApresentação: Paulo OzakiProdução: Agro ResenhaConvidado: Antônio da LuzEdição: Senhor A - https://www.instagram.com/senhor_a_/ Ediçao Senhor ASee omnystudio.com/listener for privacy information.

This week's podcast is about scale advantages. Which are different than economies of scale.You can listen to this podcast here, which has the slides and graphics mentioned. Also available at iTunes and Google Podcasts.Here is the link to the TechMoat Consulting.Here is the link to our Tech Tours.5 Things People Get Wrong about Scale Advantages, Economies of Scale and MoatsThere are lots of absolute (not relative) scale advantage. Growth is the default business strategy.Scale advantages are bigger (and more vague) than economies of scaleScale advantages can cascadeScale disadvantages (diseconomies of scale, big company disease) are under-rated and under-measuredYou need to separate barriers from competitive advantages. And measure each specifically.I want to know 3 things:Barriers to entry against new entrants.What specific CRAS to reproduce?What is the cost, difficulty and timing to enter?Competitive advantage against rivalsWhich CAs specifically? With measurements.The incumbent or rival response---------I write, speak and consult about how to win (and not lose) in digital strategy and transformation.I am the founder of TechMoat Consulting, a boutique consulting firm that helps retailers, brands, and technology companies exploit digital change to grow faster, innovate better and build digital moats. Get in touch here.My book series Moats and Marathons is one-of-a-kind framework for building and measuring competitive advantages in digital businesses.This content (articles, podcasts, website info) is not investment, legal or tax advice. The information and opinions from me and any guests may be incorrect. The numbers and information may be wrong. The views expressed may no longer be relevant or accurate. This is not investment advice. Investing is risky. Do your own research.Support the show

Nesse episódio especial convidamos nossa querida psicóloga do SciCast, Dani Almeida, e conversamos sobre sua tragetória acadêmica, produção científica, vida pessoal, SciCast, psicologia, SUS e muito mais! Patronato do SciCast: 1. Patreon SciCast 2. Apoia.se/Scicast 3. Nos ajude via Pix também, chave: contato@scicast.com.br ou acesse o QRcode: Sua pequena contribuição ajuda o Portal Deviante a continuar divulgando Ciência! Contatos: contato@scicast.com.br https://twitter.com/scicastpodcast https://www.facebook.com/scicastpodcast https://instagram.com/scicastpodcast Fale conosco! E não esqueça de deixar o seu comentário na postagem desse episódio! Expediente: Produção Geral: Tarik Fernandes e André Trapani Equipe de Gravação: Tarik Fernandes, Marcelo de Matos, André Trapani, Daniele Silva Citação ABNT: Scicast #647: Psicologia social e SUS, com Daniele Almeida. Locução: Tarik Fernandes, Marcelo de Matos, André Trapani, Daniele Silva. [S.l.] Portal Deviante, 08/06/2025. Podcast. Disponível em: https://www.deviante.com.br/podcasts/scicast-647 Imagem de capa: https://site.cfp.org.br/publicacao/referencias-tecnicas-para-atuacao-de-psicologasos-nos-servicos-hospitalares-do-sus/ Para apoiar o Pirulla, use o Pix abaixo: pirula1408@gmail.com Em nome de Marcos Siqueira (primo do Pirulla) [caption id="attachment_65160" align="aligncenter" width="300"] QR code PIX[/caption] https://www.youtube.com/watch?v=BecoooBM7ME&t=2170s Site: https://www.pirulla.com.br/ Carta colaborativa: ciência pela integridade da informaçãoFormulário para indicação de apoio Referências e Indicações É realmente possível fazer Jejum de Dopamina? E o que tem de ciência nessa nova moda de produtividade?– 14 Faian (Spin#1667 – 04/06/2022) Por que pedimos desculpas? - Parte 1 de 2 Vício em internet: teria a trolagem ido longe demais? Posts de Daniele Almeida no Deviante E tem psicólogo no CRAS? InstagramSee omnystudio.com/listener for privacy information.

On this episode of Background Check Radio, Kevin Bachman is joined by fellow IQubed Advisors' colleagues Nick Fishman, Bianca Lager and Jason Morris. We discussed the state of the industry, our concern about limited new product innovation, the growing gap between large and small CRAs, and how the guidance withdraws from the CFPB will affect screeners and employers.

Les invitées :· Charlotte Guichard, professeure à l'École Normale supérieure· Sophie Cras, maîtresse de conférences à Paris-I Le livre : Vendre son art. De la Renaissance à nos jours, Paris, Seuil, « L'Univers historique », 2025. La discussion :· Un regard sur le « premier » marché de l'art sur une longue durée (1:00)· Les sources émanant des artistes (6:25)· Qu'est-ce qui fait la valeur d'une œuvre ? styles, formats, sujets… (9:15)· Une « économie de l'attachement » entre les artistes et leurs clients (16:00)· Des artistes pas toujours libres de vendre (26:45)· La création façonnée par les stratégies économiques ? (32:45)· Vendre son art à Paris, à New York, en Chine… (44:00) Le conseil de lecture : Réunir les bouts du monde : art, histoire esclavage en mémoired'Elvan ZabunyanUn podcast créé, animé et produit par André Loez et distribué par Binge Audio. Contact pub : project@binge.audioDistribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Kevin Bachman is joined by his IQubed Advisors colleagues Jason Morris and Bianca Lager to recap the 2025 Mid Year PBSA Conference. We discussed the educational opportunities (too few) the exhibit hall hours (too much) and how businesses that don't go are affected (negatively).

durée : 00:06:34 - La Revue de presse internationale - par : Catherine Duthu - Le Lesotho, pays pauvre d'Afrique australe, entièrement enclavé dans l'Afrique du Sud, est en tête de la liste des nombreux pays frappés par les droits de douane additionnels massifs présentés mercredi par Donald Trump. Des entreprises textiles américains y ont délocalisé leur production.

After the failed assassination attempt of a former President, it seems like every single group completely lost their mind and connection to reality. Some even suggest that the inch separating him from death actually changed or split our timeline. This brings us to the fascinating works of Ingersoll Lockwood, a 19th-century author who wrote about a character named Baron Troomp. This Barron (like Baron) had a mentor named Don, a strange connection to Russia, german ancestory, a Troomp Castle or Tower, and in the final novel a candidate is unexpectedly elected to President causing New York to explode into riots with a leftist mob marching on 5th Avenue where Trump Tower is today. These motifs have people wondering if Trump, or maybe Lockwood, is a time traveler, especially since Trump's uncle handled the papers of Nikola Tesla who also lived in New York at the same time as Lockwood. Considering the seeming predictions of the Simpsons and Back to the Future II, not to mention a Marge Simpson coffin recently found dating to 3,000 years ago in Egypt, the story seems to get every stranger. -FREE ARCHIVE & RSS: https://www.spreaker.com/show/the-secret-teachings Twitter: https://twitter.com/TST___Radio Facebook: https://www.facebook.com/thesecretteachings WEBSITE (BOOKS, RESUBSCRIBE for early show access): http://thesecretteachings.info Paypal: rdgable@yahoo.com CashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.com

The discussion focuses on the role of economic development agencies, such as RDAs and CDAs, in the development process. RDAs, with state-granted powers, create CRAs to enable tax increment financing, aiming to boost job creation, sales tax, and city beautification. Developers should collaborate with these agencies, securing political and taxing entity support for success. The Salt Lake City RDA is noted for its significant resources, including a loan fund for affordable housing and downtown revitalization. The conversation also highlights the importance of relationships with site selectors, brokers, and developers, as well as using incentives like tax increment financing to attract businesses. Beautification, walkability, and high-quality buildings are emphasized as key factors in development projects.Chapters00:00Introduction and Setting00:38Different Government Agencies Involved in Development01:26Role of the Redevelopment Agency (RDA)04:24Community Reinvestment Areas (CRA) and Project Specifics07:10Utilizing Economic Development Tools for Impediments09:33City Goals: Jobs, Sales Tax, and Beautification10:31Different Economic Development Goals for Each Community13:02Sales Tax as the Main Revenue Generator for Cities14:24Involvement of Taxing Entities for Personal and Real Property Projects19:36Role of the Economic Development Director and Collaboration21:24Approaching Economic Development Agencies and Building Relationships24:06Political Buy-In and Involvement of Taxing Entities30:24Redevelopment Agencies and Low to Moderate Income Housing32:23Funding and Financing Options for Developers33:56Activating Downtown Areas and Reinvesting in Communities34:31Supporting Small Businesses and Economic Development38:38Attracting Businesses and Initiating Conversations39:08Understanding Motivators for Businesses and Developers47:45Incentives for Developers and Aesthetics of Projects49:51Beautification and Walkability in Community Development56:12Other Tools and Incentives for Economic Development